Advanced tech propels modern drug discovery.

Priya Nair*

Department of Pharmaceutical Sciences, Indian Institute of Science, Bengaluru, India

Introduction

This article explores the substantial role of Artificial Intelligence (AI) in transforming drug discovery. AI accelerates various stages, from initial target identification and lead compound generation to optimizing preclinical and clinical development. It emphasizes AI's potential to reduce costs and timelines in finding new medicines [1].

Here's the thing, phenotypic screening remains a powerful tool in drug discovery, especially for complex diseases. This review highlights its current impact, discussing how it's evolving with new technologies to identify novel mechanisms of action and drug targets, offering a fresh perspective beyond purely target-based approaches [2].

What this really means is that organ-on-a-chip technology is bridging a critical gap in drug development. This paper delves into how these microphysiological systems provide more physiologically relevant models than traditional cell cultures. They improve drug efficacy and toxicity prediction, reducing reliance on animal testing [3].

Let's break it down: computational methods are absolutely central to modern drug discovery. This article reviews the significant advancements in computational approaches, including molecular docking, dynamics simulations, and virtual screening. These methods showcase their role in accelerating the identification and optimization of potential drug candidates [4].

This paper discusses how Artificial Intelligence and Machine Learning (ML) are revolutionizing the entire drug discovery and development pipeline. It highlights their applications in predicting compound properties, designing novel molecules, repurposing existing drugs, and streamlining clinical trials. This fundamentally changes how new therapies are brought to patients [5].

Identifying and validating drug targets is foundational, and this article reviews the latest progress in that area. It covers modern genomic, proteomic, and computational strategies used to pinpoint disease-relevant targets. It also discusses innovative methods for confirming their therapeutic potential, which is crucial for successful drug development [6].

Here's the thing: computational chemistry plays a massive role in designing new drugs. This review demonstrates its impact, explaining how simulations and modeling techniques help predict molecular interactions, optimize compound structures, and accelerate lead optimization. This makes the drug design process more efficient and targeted [7].

This paper highlights how 'omics' technologies—genomics, proteomics, metabolomics—are transforming drug discovery. It details current strategies using these high-throughput methods to uncover disease biomarkers, identify new therapeutic targets, and personalize medicine. It also discusses the challenges of integrating and interpreting such vast datasets [8].

When it comes to small molecule drugs, this article summarizes recent advancements. It covers emerging technologies for synthesizing and screening diverse chemical libraries, as well as the identification of novel targets and pathways. This underscores the enduring importance of small molecules in developing effective treatments [9].

Let's consider the progress in therapeutic antibody discovery. This paper discusses the latest innovations in antibody engineering, display technologies, and bispecific antibodies. These developments are leading to more potent, specific, and safer antibody-based drugs for a range of diseases, including cancer and autoimmune disorders [10].

Conclusion

Modern drug discovery is undergoing significant transformation, embracing advanced technologies to accelerate and refine the process. Artificial Intelligence (AI) and Machine Learning (ML) play a central role, streamlining target identification, lead compound generation, and optimizing preclinical and clinical development, ultimately reducing costs and timelines in finding new medicines. These intelligent systems also help predict compound properties, design novel molecules, and repurposing existing drugs. Alongside AI, computational methods, including molecular docking, dynamics simulations, and virtual screening, are critical for accelerating the identification and optimization of potential drug candi-

***Correspondence to:** Priya Nair, Department of Pharmaceutical Sciences, Indian Institute of Science, Bengaluru, India. E-mail: priya.nair@iisc.ac.in

Received: 01-May-2025, Manuscript No. aajcrp-177; **Editor assigned:** 05-May-2025, Pre QC No. aajcrp-177 *(PQ)*; **Reviewed:** 23-May-2025, QC No. aajcrp-177; **Revised:** 03-Jun-2025, Manuscript No. aajcrp-177 *(R)*; **Published:** 12-Jun-2025, DOI: 10.35841/aajcrp.7.2.177

Citation: Nair P. Advanced tech propels modern drug discovery. aajcrp. 2025;08(02):177.

dates. Phenotypic screening continues to be a powerful tool, particularly for complex diseases, evolving with new technologies to identify novel mechanisms of action and drug targets. Organ-on-a-chip technology bridges critical gaps by offering more physiologically relevant models, which improves drug efficacy and toxicity prediction while reducing reliance on animal testing. Identifying and validating drug targets remains foundational, utilizing modern genomic, proteomic, and computational strategies to pinpoint and confirm disease-relevant targets. 'Omics' technologies, such as genomics, proteomics, and metabolomics, further transform discovery by uncovering disease biomarkers, identifying new therapeutic targets, and advancing personalized medicine. Progress in small molecule drug discovery involves emerging technologies for synthesizing and screening chemical libraries, along with the identification of novel targets and pathways. Furthermore, innovations in therapeutic antibody discovery, including engineering and display technologies, are leading to more potent, specific, and safer antibody-based drugs for various diseases.

References

1. Rahul P, Chirakal TS, Anupa CV. Artificial intelligence in drug discovery: *From molecule to medicine. Saudi Pharm J.* 2024;32:101968.
2. Lazo BR, Castro DOG, Escribano MJLAE. Phenotypic screening in drug discovery: current impact and future perspectives. *Cell Mol Life Sci.* 2022;79:384.
3. Zhang Z, Zhou B, He Y. Organ-on-a-chip systems in drug discovery and development. *Adv Drug Deliv Rev.* 2023;196:114920.
4. Sun Y, Yang J, *Hu M. Advances in computational drug discovery. Drug Discov Today.* 2021;26:3001-3011.
5. Wang X, Chen C, Liu Y. Revolutionizing drug discovery and development: *The transformative role of artificial intelligence and machine learning. Cell Biosci.* 2024;14:31.
6. Zhang Z, Lin Z, Huang Y. Drug target identification and validation: current progress and future directions. *Expert Opin Ther Targets.* 2023;27:387-400.
7. Kumar G, Kumar R, *Singh AK. Computational Chemistry and Its Impact on Drug Discovery. Curr Pharm Des.* 2022;28:2364-2375.
8. Lin Z, Jiang X, Zhong C. Omics approaches in drug discovery and development: current strategies and future challenges. *Expert Opin Drug Discov.* 2020;15:1017-1031.
9. Wang H, Fu Y, Xu J. Advances in small molecule drug discovery: new technologies and targets. *Acta Pharmacol Sin.* 2021;42:1573-1582.
10. Liu X, Xu J, *Xu Y. Recent Advances in Therapeutic Antibody Discovery and Development. Front Pharmacol.* 2022;13:951563.

Citation: *Nair P. Advanced tech propels modern drug discovery. aajcrp. 2025;08(02):177.*